publication venue for
- Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. 2005
- Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.. 73. 2024
- Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.. 72. 2023
- Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.. 72. 2022
- Establishment of a mechanism-based in vitro coculture assay for evaluating the efficacy of immune checkpoint inhibitors.. 71. 2022
- Long-term expression changes of immune-related genes in prostate cancer after radiotherapy. 2021
- Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21.. 71. 2021
- Impact of preoperative plasma levels of interleukin 6 and interleukin 6 soluble receptor on disease outcomes after radical cystectomy for bladder cancer. 2021
- Tumor immune microenvironment in brain metastases from gynecologic malignancies.. 70. 2021
- Combining UBR5 and CD163+ tumor-associated macrophages better predicts prognosis of clear cell renal cell carcinoma patients.. 70. 2021
- Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration.. 70. 2021
- PD-L1 expression in sebaceous carcinomas.. 70. 2021
- Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.. 70. 2020
- Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide.. 70. 2020
- Prevention of liver metastases through perioperative acute CpG-C immune stimulation.. 69. 2020
- Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients.. 68. 2019
- Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition.. 68. 2019
- Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models.. 66. 2016
- Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1.. 64. 2014
- Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study.. 64. 2014
- Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy.. 63. 2014
- CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis.. 62. 2013
- Mast cells impair the development of protective anti-tumor immunity.. 61. 2012
- Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor.. 61. 2011
- CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.. 61. 2011
- Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.. 61. 2011
- Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.. 60. 2011
- Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors.. 60. 2011
- Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention?. 60. 2011
- Impact of minimal tumor burden on antibody response to vaccination.. 60. 2011
- WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.. 59. 2010
- Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity.. 59. 2010
- Chordoma and chondrosarcoma gene profile: implications for immunotherapy.. 58. 2008
- Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects.. 57. 2008
- A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".. 56. 2007
- A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors.. 57. 2007
- NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy.. 56. 2007
- Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals.. 56. 2006
- Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients.. 56. 2006
- Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.. 54. 2005
- A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation.. 54. 2005
- Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.. 54. 2005
- Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells.. 54. 2005
- Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies.. 51. 2002
- Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors.. 49. 2000
- In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors.. 47. 1999
- Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen.. 47. 1998
- Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104.. 44. 1997
- Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors.. 41. 1995
- Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factor.. 41. 1995
- Keyhole limpet hemocyanin contains Gal(beta 1-3)-GalNAc determinants that are cross-reactive with the T antigen.. 40. 1995
- Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.. 39. 1994
- Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.. 39. 1994
- Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes.. 38. 1994
- IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells.. 36. 1993
- Interleukin-6 and renal cell cancer: production, regulation, and growth effects.. 35. 1992
- Reactivity of a human monoclonal antibody against carcinomas and other lesions of the colon.. 28. 1989
- Navigating TAM receptor dynamics in tumour immunotherapy. 2025
- Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. 2022
- Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer. 2017
- Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. 2011
- CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. 2011